Australia Drug for Prophylactic Human Papillomavirus Vaccines - Market Analysis to 2022

Order report by calling at +1 888 391 5441 OR send an email on with (PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Australia Drug Forecast and Market Analysis to 2022) / report name in subject line and your contact details.


The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

Researcher expects HPV vaccine coverage rates in Australia to remain relatively high throughout the forecast period, driven by a successful school-based immunization program. The inclusion of males in the school immunization program from 2013 will drive the expansion of the HPV vaccines market over the forecast period. Researcher expects that following approval Merck's nine-valent vaccine V503 will be quickly adopted into the Australian school-based immunization program, and this will provide an additional boost to HPV vaccine sales in Australia.


Complete report is available @ .



  • Overview of Prophylactic Human Papillomavirus Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the Australia including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the Australia from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Australia Prophylactic Human Papillomavirus Vaccines disease market.


Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prophylactic Human Papillomavirus Vaccines
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in the Australia


Request a sample of this report @ .


List of Tables

Table 1: Histological Progression Towards Cervical Cancer 14
Table 2: Diseases Associated with HPV Infection and Their Associated Symptoms 16
Table 3: Marketed Vaccines for HPV, 2014 22
Table 4: Product Profile - Gardasil 24
Table 5: Phase III Efficacy Trials - Gardasil 26
Table 6: Safety Profile - Gardasil 27
Table 7: Gardasil SWOT Analysis, 2014 27
Table 8: Product Profile - Cervarix 29
Table 9: Phase III Efficacy Trials - Cervarix 30
Table 10: Safety Profile - Cervarix 31
Table 11: Cervarix SWOT Analysis, 2014 32
Table 12: Overall Unmet Needs - Current and Future Level of Attainment 34
Table 13: HPV Vaccines - Phase Pipeline, 2014 51
Table 14: Product Profile - V503 53
Table 15: V503 SWOT Analysis, 2013 58
Table 16: Bivalent Vaccine (Xiamen Innovax) SWOT Analysis, 2014 61
Table 17: Sales Forecasts ($) for HPV Vaccines in Australia, 2012-2022 64
Table 18: Key Events Impacting Sales for HPV Vaccines in Australia, 2012-2022 66
Table 19: Australia HPV Vaccine Market - Drivers and Barriers, 2013 66
Table 20: Key Launch Dates 82
Table 21: Key Patent Expiries 82
Table 22: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 87


Buy a copy of this report @ .


Contact / Call +1 888 391 5441 for further information on “PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Australia Drug Forecast and Market Analysis to 2022report OR for any other market research and intelligence needs you may have for your business.